534572-58-2

Upstream product

• 534572-56-0 3,17β-dibenzyloxy(11β-toluenesulfonyloxymethyl)estra-1,3,5(10)-triene 
• 534572-55-9 3,17β-bis(benzyloxy)-11α-hydroxymethylestra-1,3,5(10)-triene 
• 534572-54-8 3,17β-dibenzyloxy-11-methylenestra-1,3,5(10)-triene 
• 40128-86-7 3,17β-Bis(benzyloxy)estra-1,3,5(10),9(11)-tetraene 
• 89155-71-5 (8S,9S,13S,14S,17S)-3,17-bis(benzyloxy)-13-methyl-6,7,8,9,12,13,14,15,16,17-decahydro-11H-cyclopenta[a]phenanthren-11-one 
• 40128-87-8 11α-hydroxy-3,17β-dibenzyloxyoestra-1,3,5(10)-triene 
• 69455-04-5 3,17β-bis(benzyloxy)estra-1,3,5(10)-triene 
• 100-39-0 benzyl bromide 
• 50-28-2 estradiol 
• 534572-57-1 3,17β-dibenzyloxy-11β-cyanomethylestra-1,3,5(10)-triene 

Downstream Products

• 849241-34-5 O-ethyl (3,17β-dibenzyloxyestra-1,3,5(10)-trien-11β-yl)thioacetate 

Relevant academic research and scientific papers

11beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer

The present invention relates to novel 11-β estradiol ester compounds and their use as locally active estrogens in the treatment of the symptomology of menopause and to treat estrogen sensitive cancers, including breast cancer.

Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens

We have synthesized derivatives of estradiol that are structurally modified to serve as "soft" estrogens and act within a geographically limited area of the body; estrogens without systemic action. We have previously shown with 16α-substituted analogues o